Innovative Historical Income Statement
| 002173 Stock | 8.24 0.14 1.67% |
Historical analysis of Innovative Medical income statement accounts such as Selling General Administrative of 40.6 M, Total Revenue of 550.5 M or Cost Of Revenue of 417 M can show how well Innovative Medical Management performed in making a profits. Evaluating Innovative Medical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Innovative Medical's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Innovative Medical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Innovative Medical is a good buy for the upcoming year.
Innovative |
About Innovative Income Statement Analysis
Innovative Medical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Innovative Medical shareholders. The income statement also shows Innovative investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Innovative Medical Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Innovative Medical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Cost Of Revenue
Cost of Revenue is found on Innovative Medical income statement and represents the costs associated with goods and services Innovative Medical provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Innovative Medical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Innovative Medical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Innovative Medical Management. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. At present, Innovative Medical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 120.8 M, whereas Net Loss is forecasted to decline to (99.4 M).
| 2022 | 2024 | 2025 (projected) | Other Operating Expenses | 3.7M | 3.3M | 4.8M | Gross Profit | 30.6M | 83.0M | 120.8M |
Innovative Medical income statement Correlations
Click cells to compare fundamentals
Innovative Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Innovative Medical income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 7.6M | 6.1M | 3.4M | 3.6M | 4.2M | 4.2M | |
| Net Income Applicable To Common Shares | 29.7M | (1.1B) | (314.5M) | (105.2M) | (94.7M) | (99.4M) | |
| Net Income | (314.5M) | (105.2M) | (73.7M) | (34.3M) | (30.9M) | (32.4M) | |
| Selling General Administrative | 43.7M | 42.5M | 38.8M | 37.7M | 43.3M | 40.6M | |
| Total Revenue | 724.2M | 711.5M | 709.7M | 805.6M | 926.4M | 550.5M | |
| Operating Income | (101.5M) | (79.4M) | (91.9M) | (34.2M) | (30.8M) | (29.3M) | |
| Cost Of Revenue | 696.4M | 665.4M | 679.1M | 713.4M | 820.4M | 417.0M | |
| Income Before Tax | (285.0M) | (104.8M) | (75.3M) | (35.0M) | (31.5M) | (33.0M) | |
| Income Tax Expense | 66.2M | (646.2K) | 29.5M | 273.5K | 314.6K | 298.8K | |
| Minority Interest | 999.2K | (108.8K) | 172.5K | 550.35 | 495.32 | 470.55 | |
| Gross Profit | 27.8M | 46.2M | 30.6M | 92.2M | 83.0M | 120.8M | |
| Other Operating Expenses | 6.2M | 6.3M | 3.4M | 3.7M | 3.3M | 4.8M | |
| Net Income From Continuing Ops | (314.4M) | (105.1M) | (73.9M) | (34.3M) | (30.9M) | (32.4M) | |
| Ebit | (123.9M) | (111.6M) | (79.4M) | (91.9M) | (82.7M) | (78.6M) | |
| Total Operating Expenses | 825.8M | 790.9M | 801.6M | 839.8M | 965.8M | 782.7M | |
| Tax Provision | 29.5M | 273.5K | (1.4M) | (676.5K) | (608.9K) | (578.4K) | |
| Net Interest Income | (1.1M) | 6.1M | 10.3M | 12.7M | 14.6M | 15.3M | |
| Interest Income | 7.2M | 13.1M | 14.6M | 17.4M | 20.0M | 11.4M | |
| Ebitda | (1.0B) | (165.5M) | 18.7M | 38.3M | 34.5M | 36.2M | |
| Reconciled Depreciation | 111.8M | 117.5M | 110.3M | 106.7M | 122.7M | 116.0M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Innovative Stock
Innovative Medical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Innovative Medical shareholders. The income statement also shows Innovative investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).